Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating promising results in addressing excess mass and related non-insulin-dependent disease. Initial data suggest a unique https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/